Subgroup Analysis of Cadonilimab as 1L Therapy for Advanced Cervical Cancer Reported
The subgroup analysis demonstrated that cadonilimab treatment significantly improved progression-free survival (PFS) and overall survival (OS) across different patient subgroups, including: levels of PD-L1 expression, prior treatment with concurrent chemoradiotherapy (CCRT), bevacizumab use, and age of the patients (≥65, <65). These results further demonstrate the clinical value and the global women’s health impact of cadonilimab in advancing the treatment standard for advanced cervical cancer.
Share:
More News
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.
“Many solid tumors remain difficult to treat despite advances in immunotherapy,” said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. “Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents.”
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the first patient has been dosed in a Phase III clinical trial evaluating its novel Nectin-4-targeting ADC (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).